

NOXXON PHARMA AG TO PRESENT AT SACHS ASSOCIATES' 5th ANNUAL NORTH AMERICA FORUM FOR INVESTING AND PARTNERING IN BIOTECH

Berlin, Germany, March 13, 2006 -- NOXXON Pharma AG (NOXXON), the next generation aptamer company and leader in Spiegelmer therapeutics, will be presenting at the Sachs Associates' North America Forum for Investing and Partnering on March 14th in the Copley Plaza Hotel in Boston, MA.

Thomas Klein, Chief Executive Officer of NOXXON, will provide a corporate overview of NOXXON, including the current status of development of the company's next generation aptamers and its recent licensing and strategic alliance activities. "The conference provides an ideal forum to both present our progress in developing Spiegelmers into drugs and highlight NOXXON's emergence as a partner to the pharmaceutical industry," Mr Klein said. "We want to deliver this message to the investment community as directly as possible." NOXXON's presentation is scheduled for March 14, 2.25 PM.

About NOXXON Pharma AG, the next generation aptamer company:

Based on one of the largest and best protected patent portfolio, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) bind highly specific to the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info: <http://www.noxxon.net>

About the event:

Sachs Associates' North America Forum for Investing and Partnering is a leading international meeting for emerging growth and established biotech companies from overseas to address investors, their advisers and the media. It is attended by over 500 delegates giving listed companies and IPO prospects the opportunity to make direct contact with key

members of the investment community. The forum is regarded as highly transactional. For additional information or a schedule of presentations visit: <http://www.sachsforum.com>

NOXXON General contact: Esther Brimacombe
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49 30 72 62 47 0
FAX: + 49 30 72 62 47 225
Email: ebrimacombe@noxxon.net

US contact: Steffen Helmling, PhD
VP of Business Development
NOXXON Pharma AG - US-office
One Broadway, 14th floor
Cambridge, MA 02142, USA

Telephone: + 1 617-475-1605
FAX: + 1 617-475-6099
Email: shelmling@noxxon.net